GPT and metabolic dysfunction-associated steatotic liver disease: In addition, a recent double-blind, placebo-controlled, randomized phase 2 trial conducted in Japanese patients with NAFLD showed that pemafibrate significantly improved MRI-based liver stiffness and reduced levels of ALT and surrogate markers for liver fibrosis compared with placebo, although treatment with pemafibrate failed to reduce MRI-based liver fat content (18).